India to Iran Pharmaceutical Export (2026) — $9.3M, 79 Suppliers | TransData Nexus

India to Iran Pharmaceutical Export (2026) — $9.3M, 79 Suppliers | TransData Nexus | TransData Nexus

Top Pharmaceutical Formulations — India to Iran

#	Formulation	Value	Share
1	Inactivated Poliomyelitis Vaccine B.p. Brand Name : Shan Ipv 2.5ml	$994.8K	10.7%
2	Betamethasone Sodium Phosphate and Betam	$525.2K	5.6%
3	Sodium Chloride Intravenous Infusion BP	$481.7K	5.2%
4	Pharmaceutical Medicine Products Diclofe	$344.8K	3.7%
5	Ketorolac Trometamol Md Tablets 10 MG (ketanov Tablets)	$228.9K	2.5%
6	Dicyclomine Hydrochloride Oral Solution	$215.3K	2.3%
7	Veterinary Medicine, Veterinary Medicinal Preparation Not for Human Use Not Els…	$215.1K	2.3%
8	Active Pharmaceutical Ingredient- Ketamine Hydrochloride USP	$191.5K	2.1%
9	Sodium Chloride Injection IP 0.9% 500 ML	$187.0K	2.0%
10	Maprotiline Hydrochloride Tablets USP 25	$152.1K	1.6%
11	Mito Spal -t 500	$148.1K	1.6%
12	Pharmaceutical Medicine Products Combipa	$140.3K	1.5%
13	Sodium Chloride (0.3% W/v) & Glucose (3.33% W/v) Intravenous Infusion BP 500 ML	$109.3K	1.2%
14	Pharmaceutical Medicine Products,ceftria	$106.0K	1.1%
15	Rabies Antiserum 1000 IU (vinrab) (5ml Pack)	$105.5K	1.1%

India exports 20+ pharmaceutical formulations to Iran with a combined trade value of $9.3M. Key products include Vaccine ($995K), Sodium ($525K), Ketorolac ($229K), Rifampicin ($105K), Isoniazid ($100K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 1,098 verified Indian Customs (DGFT) shipment records.

Top Pharmaceutical Products — India to Iran Trade Routes

1Vaccine$995K

2Sodium$525K

3Ketorolac$229K

4Rifampicin$105K

5Isoniazid$100K

These are the top pharmaceutical products exported from India to Iran, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Iran buyers, regulatory requirements, and logistics for that specific product corridor. Products include — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.

Top Indian Exporters to Iran

1S.d.pharmaceuticals

$1.7M

2Sanofi Healthcare India Private Limited

$995K

3Ahlcon Parenterals (india) Limited

$626K

4Antila Lifesciences Private Limited

$619K

5Dips Bioscience Private Limited

Port Analysis — India to Iran Pharmaceutical Shipments

Indian Export Ports

NHAVA SHEVA SEA (INNSA1)13.6%

CHENNAI AIR0.1%

MUNDRA SEA (INMUN1)3.2%

CHAWAPAYAL ICD (INCPR6)1.1%

JNPT11.7%

Iran Import Ports

Bandar Abbas21.1%

BANDAR ABBAS34.6%

TEHRAN11.1%

IMAM KHOMEINI ARPT1.5%

Kabul8.9%

Trade Statistics

Total Value$9.3M

Shipments1,098

Indian Exporters79

Iran Buyers88

Avg Shipment$9K

Products657

Other Destinations

United States$8.8B United Kingdom$1.2B Canada$1.1B France

Last updated: March 28, 2026

India–Iran Pharmaceutical Trade Corridor Analysis

Historical evolution, India's market position, and recent developments

1Trade Corridor Evolution

The India-Iran pharmaceutical trade corridor has experienced significant fluctuations over the past decades, influenced by geopolitical dynamics and economic policies. In the fiscal year 2018-19, India's pharmaceutical exports to Iran were valued at approximately $3.5 billion, reflecting a robust trade relationship. However, this figure declined sharply in subsequent years, reaching $1.45 billion in 2021-22 and further decreasing to $1.24 billion in 2024-25.

The decline in exports can be attributed to several factors, including the re-imposition of international sanctions on Iran, which affected its purchasing power and import capabilities. Additionally, the global COVID-19 pandemic disrupted supply chains, leading to a reduction in trade volumes. Despite these challenges, the pharmaceutical sector remains a critical component of bilateral trade, with India continuing to supply a range of essential medicines to Iran.

2India's Market Position

India holds a significant position in Iran's pharmaceutical import market, supplying a diverse array of finished pharmaceutical formulations. In 2024, India's pharmaceutical exports to Iran were valued at $24.9 million, with major products including inactivated poliomyelitis vaccine, betamethasone sodium phosphate, and sodium chloride intravenous infusion.

While specific data on India's share of Iran's total pharmaceutical imports is not readily available, the consistent presence of Indian pharmaceutical products in Iran's market underscores the strategic importance of this trade corridor. India's competitive pricing, quality manufacturing standards, and adherence to international regulatory norms have bolstered its position as a preferred supplier of pharmaceutical products to Iran.

Iran Regulatory Landscape for Indian Pharmaceutical Exports

Registration process, GMP requirements, import documentation

1Registration Process

To export finished pharmaceutical formulations to Iran, Indian companies must navigate a structured registration process overseen by Iran's National Drug Regulatory Authority (NDRA), which adheres to WHO-GMP standards. The process typically involves submitting a comprehensive dossier that includes detailed information on the product's quality, safety, and efficacy. This dossier is generally prepared in the Common Technical Document (CTD) format, as recommended by the International Council for Harmonisation (ICH). The CTD comprises five modules:

Module 1: Administrative and prescribing information, tailored to regional requirements.
Module 2: Summaries of quality, non-clinical, and clinical data.
Module 3: Quality (chemistry, manufacturing, and controls) information.
Module 4: Non-clinical study reports.
Module 5: Clinical study reports.

The CTD format is widely accepted for regulatory submissions and is mandatory for WHO prequalification as of January 2021. (extranet.who.int)

The approval timeline for product registration in Iran can vary, but it generally spans several months, depending on the complexity of the product and the completeness of the submitted dossier. While specific fees are not publicly disclosed, applicants should anticipate costs associated with dossier preparation, submission, and potential facility inspections.

2GMP & Facility Requirements

Iran requires that manufacturing facilities comply with Good Manufacturing Practice (GMP) standards to ensure the quality and safety of pharmaceutical products. For foreign manufacturers, this includes providing evidence of GMP certification from recognized authorities, such as the WHO. The inspection process may involve on-site evaluations to verify compliance with GMP standards. Mutual recognition agreements between Iran and other countries can facilitate this process, but manufacturers should be prepared for potential inspections and audits.

3Import Documentation

To import pharmaceutical products into Iran, companies must obtain an import license from the Ministry of Health (MOH). Required documentation typically includes:

Certificate of Pharmaceutical Product (CPP): Verifies that the product is authorized for sale in the country of origin.
Certificate of Analysis (CoA): Confirms that the product meets specified quality standards.
GMP Certificate: Demonstrates that the manufacturing facility adheres to GMP standards.

Customs procedures for pharmaceutical imports into Iran involve submitting these documents to the relevant authorities for review and approval. It's essential to ensure that all documentation is accurate and complete to facilitate a smooth import process.

TransData Nexus Research · Iran regulatory databasesMar 2026

Product Categories & Therapeutic Trends — India to Iran

Dominant categories, emerging opportunities, and demand drivers

1Dominant Categories

India's pharmaceutical exports to Iran are predominantly concentrated in therapeutic areas that align with Iran's pressing healthcare needs. The top export, accounting for 10.7% of the total value, is the Inactivated Poliomyelitis Vaccine B.P. Brand Name: SHAN IPV 2.5ML (Pack 2.5ML), valued at $995K. This underscores India's significant role in supporting Iran's immunization programs, particularly in combating polio.

Other leading exports include Betamethasone Sodium Phosphate and Betamethasone Acetate, a corticosteroid used to treat various inflammatory conditions, and Sodium Chloride Intravenous Infusion BP, essential for rehydration and electrolyte balance. These products collectively constitute a substantial portion of India's pharmaceutical exports to Iran, reflecting the critical demand for both immunological and supportive care treatments in the Iranian healthcare system.

2Emerging Opportunities

The Iranian pharmaceutical market presents emerging opportunities for Indian exporters, particularly in the realm of biosimilars. As Iran seeks to enhance the affordability and accessibility of biologic treatments, the demand for high-quality biosimilars is expected to rise. Indian pharmaceutical companies, with their established expertise in biosimilar development, are well-positioned to meet this demand, offering cost-effective alternatives to expensive biologic therapies.

Additionally, the global trend of patent expirations, known as patent cliffs, is creating openings for generic medications. While specific data on patent expirations in Iran is limited, the general pattern suggests potential for Indian generics to enter the market, especially in therapeutic areas where patents are nearing expiration. This scenario offers Indian exporters a chance to provide affordable alternatives to branded drugs, aligning with Iran's healthcare objectives.

3Demand Drivers

Iran's disease burden significantly influences its pharmaceutical import demand. Cardiovascular diseases (CVDs) are the leading cause of death in Iran, with a 99.28% increase in deaths attributed to CVD risk factors from 1990 to 2021. This escalating prevalence drives the need for medications targeting hypertension, hyperlipidemia, and other CVD-related conditions.

The economic burden of non-communicable diseases (NCDs), including CVDs and cancers, further underscores the demand for effective pharmaceutical interventions. In 2018, NCDs accounted for 29.90% of Iran's health expenditure, highlighting the financial strain and the necessity for cost-effective treatments. These factors collectively create a robust market for pharmaceutical products, particularly those addressing chronic diseases prevalent in the Iranian population.

TransData Nexus Research · DGFT trade data analysisMar 2026

Trade Policy & Tariff Intelligence — India and Iran

Tariff structure, trade agreements, IP and patent landscape

1Tariff & Duty Structure

Iran's tariff structure for pharmaceutical products, particularly those classified under HS codes 3003 and 3004, is characterized by Most-Favored-Nation (MFN) rates of 7.5% as of April 2022. These rates apply to a broad range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific preferential duty rates for Indian exports are not detailed in the available sources, it is common for countries to offer reduced tariffs under bilateral agreements or regional trade arrangements. Therefore, Indian pharmaceutical exporters should consult the latest trade agreements and official Iranian customs publications to determine any applicable preferential rates.

Regarding anti-dumping or countervailing duties, there is no publicly available information indicating that Iran has imposed such measures on Indian pharmaceutical products. However, trade policies can evolve, so it is advisable for exporters to monitor updates from the Iranian Ministry of Industry, Mine, and Trade and the National Drug Regulatory Authority to stay informed about any new trade remedies.

2Trade Agreements

As of March 2026, there is no publicly available information indicating the existence of a Free Trade Agreement (FTA) between India and Iran. The absence of such an agreement means that Indian pharmaceutical exports to Iran are subject to the standard MFN tariff rates. While both countries have engaged in various regional and multilateral trade agreements, the lack of a bilateral FTA suggests that pharmaceutical trade between India and Iran operates without preferential tariff treatment. Indian exporters should consider exploring potential trade agreements or negotiations that could facilitate better market access and reduced tariff barriers.

3IP & Patent Landscape

Iran's intellectual property (IP) framework, particularly concerning patents, is designed to protect innovations, including pharmaceutical formulations. The country is a member of the World Intellectual Property Organization (WIPO) and has established patent laws that align with international standards. For Indian pharmaceutical companies exporting generic drugs to Iran, it is crucial to navigate these IP provisions carefully. While Iran's patent laws provide protection for patented drugs, they also include provisions for compulsory licensing under specific conditions, such as public health emergencies. Therefore, Indian exporters should conduct thorough due diligence to ensure compliance with Iranian patent laws and assess the potential risks associated with compulsory licensing. Engaging with local legal experts familiar with Iranian IP law is advisable to mitigate risks and ensure smooth market entry.

TransData Nexus Research · Trade policy databasesMar 2026

Supply Chain & Logistics — India to Iran Pharma Shipments

Shipping routes, port infrastructure, cold chain compliance

1Shipping Routes & Transit

Pharmaceutical shipments from India to Iran primarily utilize sea and air transport, each offering distinct advantages. Sea freight is the most cost-effective method, suitable for large volumes of goods. Air freight, while more expensive, provides faster delivery, which is crucial for time-sensitive pharmaceutical products.

The International North–South Transport Corridor (INSTC) is a significant multimodal route connecting India to Russia via Iran. This corridor reduces shipping distance and transit time by up to 40% compared to traditional routes via the Suez Canal. It offers three main routes:

Sea-Land Route (Bandar Abbas – Astrakhan): Cargo is shipped from Indian ports to Bandar Abbas in southern Iran, then transported by road and rail to northern Iranian ports on the Caspian Sea, such as Bandar Anzali and Bandar Astara, and finally via the Caspian Sea to Astrakhan, Russia.

Sea-Rail Route (Chabahar – Sarakhs): Cargo is shipped from Indian ports to Chabahar Port in southeastern Iran, then transported by rail to Sarakhs on the Iran-Turkmenistan border, and from there to Central Asian countries and Russia.

Regarding transit times, sea freight from Indian ports to Iranian ports typically ranges from 7 to 14 days, depending on the specific ports and shipping conditions. Air freight offers a faster alternative, with transit times of approximately 3 to 5 days. However, recent disruptions in the Red Sea have impacted maritime routes, potentially leading to longer transit times and increased costs.

2Port Infrastructure

In India, key export ports handling pharmaceutical shipments include Nhava Sheva Sea Port (INNSA1), Chennai Air Port, and Mundra Sea Port (INMUN1). Nhava Sheva Sea Port, located near Mumbai, is the largest container port in India and handles a significant portion of the country's maritime trade. Chennai Air Port and Mundra Sea Port also play vital roles in facilitating pharmaceutical exports.

In Iran, major import ports for pharmaceutical products are Bandar Abbas, Bandar Abbas, and Tehran. Bandar Abbas is Iran's main deep-water port near the Strait of Hormuz, processing over 75–80 million tons of cargo annually, including containers, oil, and general goods. Tehran, the capital city, serves as a significant hub for air cargo, including pharmaceutical imports.

3Cold Chain & Compliance

Maintaining the integrity of temperature-sensitive pharmaceutical products is paramount. These products require strict temperature control throughout the supply chain to ensure efficacy and safety. Compliance with Good Distribution Practice (GDP) guidelines is essential, encompassing proper packaging, labeling, staff training, risk assessment, and documentation. Temperature-sensitive products, such as vaccines and biologics, typically require storage and transportation within specific temperature ranges, often between 2–8°C (36–46°F). Any deviation from these conditions can compromise product quality and patient safety. Therefore, robust cold chain management practices are critical to uphold the standards of pharmaceutical logistics.

TransData Nexus Research · DGFT port data, shipping intelligenceMar 2026

Market Opportunity Assessment — Iran for Indian Pharma

Market size, healthcare system, growth outlook

1Market Size & Growth

Iran's pharmaceutical market has experienced significant growth over the past two decades. In 2016, the market was valued at approximately $4.608 billion, up from $2.358 billion in 2008, reflecting a compound annual growth rate (CAGR) of about 9.87%. This growth is driven by factors such as an increasing population, a rising prevalence of chronic diseases, and substantial government investment in healthcare infrastructure. The market is characterized by a high dependency on imports, with imported medicines accounting for over 50% of the market value, despite local production meeting more than 95% of the market's volume needs.

The Iranian government has implemented policies to promote domestic pharmaceutical production and reduce reliance on imports. These measures include supporting local manufacturers and encouraging the development of high-tech medicines. However, the market remains attractive for foreign exporters, especially in segments where local production is limited or absent. The generic drug penetration rate is substantial, with generics constituting a significant portion of the market, driven by economic constraints and government policies favoring cost-effective medications.

2Healthcare System

Iran's healthcare system is structured into three tiers: primary, secondary, and tertiary care, with services financed through a mix of government funds, health insurance, individual payments, and out-of-pocket expenses. Approximately 9% of the country's GDP is allocated to healthcare, equating to about $475 per capita, with around 1.4% of this amount dedicated to pharmaceuticals. The government has established multiple public health insurance schemes, including the Social Security Organization, Medical Services Organization, Armed Forces Medical Services Insurance Organization, and Imam Khomeini Relief Committee, collectively covering about 90% of the population. These programs aim to provide comprehensive coverage, though challenges such as funding constraints and demographic pressures persist.

3Opportunity for Indian Exporters

The Iranian pharmaceutical market presents significant opportunities for Indian exporters, particularly in the finished pharmaceutical formulations segment. In 2022, India exported approximately $9.3 million worth of pharmaceutical products to Iran, with 79 Indian exporters supplying 88 Iranian buyers. The top products included vaccines, corticosteroids, and intravenous infusions, indicating a demand for both essential and specialized medications. Given the market's reliance on imports for high-tech and specialized drugs, Indian exporters can leverage their strengths in producing cost-effective generics and specialized formulations to meet this demand. The growth forecast for Indian pharmaceutical imports into Iran from 2025 to 2028 is positive, driven by Iran's ongoing healthcare reforms, increasing demand for affordable medications, and the strengthening of trade relations between the two countries. By focusing on high-demand therapeutic areas and ensuring compliance with Iran's regulatory standards, Indian exporters can effectively tap into this expanding market.

TransData Nexus Research · Iran healthcare dataMar 2026

Competitive Landscape — India vs Other Pharmaceutical Suppliers to Iran

Competing origins, India's edge, challenges and threats

1Competing Origins

Iran's pharmaceutical market is supplied by a diverse array of countries, including China, European Union (EU) manufacturers, domestic producers, and other emerging economies. China has been a significant supplier, particularly in the bulk drug segment, leveraging favorable trade terms and competitive pricing. European countries, notably Spain, have also been active in exporting pharmaceutical products to Iran, with imports valued at approximately $38.06 million in 2022. Domestically, Iran has developed a robust pharmaceutical industry, with biotechnology products accounting for 60% of its pharmaceutical exports as of September 2025. This domestic production not only meets a substantial portion of local demand but also contributes to export revenues. Other emerging suppliers include countries like Turkey and the United Arab Emirates, which have been increasing their presence in the Iranian market. However, specific market share data for these countries is limited.

2India's Competitive Edge

India's pharmaceutical exports to Iran have been notable, with a total export value of $9.3 million USD over 1,098 shipments from 2022 to 2026. This performance underscores India's competitive advantages in the Iranian market. Key strengths include cost competitiveness, adherence to WHO-GMP standards, a large English-speaking workforce, and a broad portfolio of pharmaceutical products. These factors enable Indian exporters to offer a diverse range of high-quality products at competitive prices, catering to various therapeutic needs in Iran.

3Challenges & Threats

Despite these advantages, Indian pharmaceutical exporters face several challenges in the Iranian market. Regulatory tightening, including compliance with the National Drug Regulatory Authority's standards, can pose obstacles. Additionally, competition from China, which has been increasing its presence in the Iranian market, particularly in the bulk drug segment, presents a threat. Quality perception issues may also arise, as Iranian consumers and healthcare providers may have concerns about the quality of imported pharmaceuticals. These challenges necessitate strategic approaches to maintain and enhance India's position in the Iranian pharmaceutical market.

TransData Nexus Research · Global trade databasesMar 2026

FAQ — India to Iran Pharmaceutical Trade

What is the total value of India's pharmaceutical export to Iran?

India exported pharmaceuticals worth $9.3M to Iran across 1,098 verified shipments.

Who are the top Indian pharmaceutical exporters to Iran?

1. S.D.PHARMACEUTICALS — $1.7M. 2. SANOFI HEALTHCARE INDIA PRIVATE LIMITED — $994.8K. 3. AHLCON PARENTERALS (INDIA) LIMITED — $625.9K. Total: 79 suppliers.

Which companies in Iran import pharmaceuticals from India?

1. TAMIN PHARMED TEHRAN — $1.4M. 2. ROUGINE DAROU CO. (P.J.S — $994.8K. 3. TO THE ORDER — $656.8K. 88 buyers total.

What pharmaceutical products does India export most to Iran?

1. Inactivated Poliomyelitis Vaccine B.p. Brand Name : Shan Ipv 2.5ml ($994.8K, 10.7%); 2. Betamethasone Sodium Phosphate and Betam ($525.2K, 5.6%); 3. Sodium Chloride Intravenous Infusion BP ($481.7K, 5.2%); 4. Pharmaceutical Medicine Products Diclofe ($344.8K, 3.7%); 5. Ketorolac Trometamol Md Tablets 10 MG (ketanov Tablets) ($228.9K, 2.5%)

Which ports handle pharmaceutical shipments from India to Iran?

Export: NHAVA SHEVA SEA (INNSA1), CHENNAI AIR, MUNDRA SEA (INMUN1), CHAWAPAYAL ICD (INCPR6), JNPT. Import: Bandar Abbas, BANDAR ABBAS, TEHRAN, IMAM KHOMEINI ARPT, Kabul.

Why does Iran import pharmaceuticals from India?

India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $9.3M corridor reflects quality compliance and pricing advantages.

What certifications do Indian pharmaceutical exporters need to supply Iran?

WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.

What is the average shipment value for India to Iran pharmaceutical trade?

$8.5K per consignment across 1,098 shipments.

How many Indian pharmaceutical companies export to Iran?

79 Indian companies. Largest: S.D.PHARMACEUTICALS with $1.7M.

How can I find verified Indian pharmaceutical suppliers for Iran?

TransData Nexus covers 79 active exporters with shipment history and trade values at transdatanexus.com.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Data Source: Indian Customs (DGFT) export shipping bill records covering all pharmaceutical shipments from India.
2.Country Matching: Shipments to Iran identified using destination country codes from customs declarations.
3.Statistical Normalization: Values are statistically normalized to remove outlier transactions and ensure accurate market share representation.
4.Coverage: 1,098 verified shipments from 79 Indian exporters to 88 Iran buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

79 Exporters

88 buyers tracked

Expert-Reviewed

By pharmaceutical trade specialists

India to Iran Pharmaceutical Export